Stimuvax Therapeutic Cancer Vaccine – Phase II Data Highlight Three-Year Survival Results for Lung Cancer Patients
Stimuvax Phase III Trial – the START Study – Open for Patient Enrollment
DARMSTADT, Germany, SEOUL, South Korea, September 5, 2007 - Merck KGaA has announced three-year survival results from a randomized Phase II trial for the Stimuvax® MUC-1 vaccine in non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) Congress in Seoul, South Korea. The results suggest that Stimuvax combined with best supportive care (BSC) may provide survival benefits to patients with unresectable stage IIIB NSCLC who had either responded or had stable disease after initial radio-chemotherapy compared to patients receiving BSC alone.(1)
Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto.
This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck does not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck does not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith.
Contact: Phyllis Carter Telephone +49 6151 72-7144
Merck KGaA External Communications E-mail: Media.Relations@merck.de
Hotline: +49 (0) 6151/72-5000
